Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.4K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

550
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
550
Cross-bridge Cycle01:26

Cross-bridge Cycle

123.3K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
123.3K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.1K
Muscles that Move the Arm01:31

Muscles that Move the Arm

5.0K
Nine muscles are involved in arm movements. Two of these, the pectoralis major and latissimus dorsi, originate from the axial skeleton and are called axial muscles. The other seven originate from the scapula and are called the scapular muscles.
The pectoralis major has two origins. Its clavicular head originates on the medial half of the clavicle. In contrast, the sternocostal head originates on the costal cartilages of ribs 1-6, the sternum, and the aponeurosis of the external oblique of the...
5.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting report: 2025 muscular dystrophy association summit on 'safety and challenges in gene therapy of neuromuscular diseases'.

Journal of neuromuscular diseases·2026
Same author

SORT LNPs encapsulating Cas9 mRNA achieve efficient editing in skeletal muscle in a dystrophic mouse model.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Meeting report: 2024 Muscular Dystrophy Association summit on 'Safety and challenges in gene therapy of neuromuscular diseases'.

Journal of neuromuscular diseases·2026
Same author

Optically isotropic fast phase modulation in 3D blue phase photonic crystals.

Scientific reports·2025
Same author

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.

Neuromuscular disorders : NMD·2025
Same author

An increase in reactive oxygen species underlies neonatal cerebellum repair.

eLife·2025

Related Experiment Video

Updated: Feb 22, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.3K

Facioscapulohumeral Muscular Dystrophy.

Alec M DeSimone1, Anna Pakula2,3, Angela Lek2,3,4

  • 1Wellstone Muscular Dystrophy Program, Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Comprehensive Physiology
|September 16, 2017
PubMed
Summary
This summary is machine-generated.

Facioscapulohumeral muscular dystrophy (FSHD) involves progressive muscle weakness due to DUX4 misexpression. Advances in understanding FSHD genetics, epigenetics, and molecular pathology are paving the way for new therapeutic strategies.

More Related Videos

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

10.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.2K

Related Experiment Videos

Last Updated: Feb 22, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.3K
Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

10.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.2K

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Physiology

Background:

  • Facioscapulohumeral muscular dystrophy (FSHD) is a common neuromuscular disorder characterized by progressive muscle weakness.
  • FSHD's etiology is complex, involving genetic and epigenetic factors, with FSHD1 linked to D4Z4 microsatellite contraction and FSHD2 to SMCHD1 gene haploinsufficiency.
  • DUX4 misexpression in skeletal muscles is a central pathogenic mechanism in both FSHD types.

Purpose of the Study:

  • To review recent advances in understanding the pathophysiology of FSHD.
  • To highlight the role of genetic and epigenetic disruptions, including DUX4 misexpression.
  • To discuss emerging therapeutic approaches for FSHD.

Main Methods:

  • Review of current literature on FSHD genetics, epigenetics, and molecular mechanisms.
  • Discussion of the application of Magnetic Resonance Imaging (MRI) in FSHD research and diagnostics.
  • Analysis of molecular pathways and genetic modifiers implicated in FSHD.

Main Results:

  • FSHD1 is associated with D4Z4 contraction on a 4qA chromosome, leading to DUX4 misexpression.
  • FSHD2 involves SMCHD1 haploinsufficiency and DUX4 misexpression.
  • Other genes like FRG1, FAT1, and SMCHD1 act as disease modifiers, contributing to diverse pathomechanisms.

Conclusions:

  • DUX4 misexpression is a key factor in FSHD pathogenesis.
  • Understanding the complex genetic and epigenetic landscape of FSHD is crucial for therapeutic development.
  • Advances in research tools and knowledge are driving the development of novel FSHD treatments.